Synapse - Works

Results (13087)

Spliceosomal disruption of the non-canonical SWI/SNF chromatin remodeling complex in SF3B1 mutant leukemias

Meeting Abstract

Inoue, D.; Guo-Liang, C.; Liu, B.; Lee, S. C.; Michel, B. C.; Pangallo, J.; D'Avino, A. R.; North, K.; Bitner, L. E.; Xiao, M.; more...
Blood (2019)

Fulltext@MSK | Save

RIG-I activation is critical for responsiveness to checkpoint blockade

Meeting Abstract

Heidegger, S.; Wintges, A.; Stritzke, F.; Steiger, K.; Koenig, P. A.; Engleitner, T.; Fischer, J. C.; Makarov, V.; Winter, C.; Rad, R.; more...
Blood (2019)

Fulltext@MSK | Save

Patient-reported outcome results from the US Life after Stopping TKIs (LAST) study in patients with chronic myeloid leukemia

Meeting Abstract

Flynn, K. E.; Weinfurt, K. P.; Lin, L.; Radich, J. P.; Schiffer, C. A.; Mauro, M. J.; Ibarz, J. P.; Moore, J. O.; Larson, R. A.; Oehler, V. G.; more...
Blood (2019)

Fulltext@MSK | Save

Maintenance decitabine (DAC) improves disease-free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults, particularly in FLT3-ITD-negative patients: ECOG-ACRIN (E-A) E2906 randomized study

Meeting Abstract

Foran, J. M.; Sun, Z.; Claxton, D. F.; Lazarus, H. M.; Arber, D. A.; Rowe, J. M.; Paietta, E.; Racevskis, J.; Altman, J. K.; Luger, S. M.; more...
Blood (2019)

Fulltext@MSK | Save

Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: Interim phase II results from an ongoing, randomized study

Meeting Abstract

DiNardo, C. D.; Schuh, A. C.; Stein, E. M.; Montesinos Fernandez, P.; Wei, A.; De Botton, S.; Zeidan, A. M.; Fathi, A. T.; Quek, L.; Kantarjian, H. M.; more...
Blood (2019)

Fulltext@MSK | Save

Primary results from the phase 3 TOURMALINE-AL1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (Pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL)

Meeting Abstract

Dispenzieri, A.; Kastritis, E.; Wechalekar, A. D.; Schönland, S. O.; Kim, K.; Sanchorawala, V.; Landau, H. J.; Kwok, F.; Suzuki, K.; Comenzo, R. L.; more...
Blood (2019)

Fulltext@MSK | Save

Extended mutational profiling by MSK-IMPACT™ identifies mutations predicting thromboembolic risk in patients with solid tumor malignancy

Meeting Abstract

Dunbar, A.; Bolton, K.; Devlin, S. M.; Sanchez-Vega, F.; Gao, J.; Mones, J. V.; Wills, J. M.; Kelly, D.; Farina, M.; Kishore, S.; more...
Blood (2019)

Fulltext@MSK | Save

Optimal dual-targeted CAR construct simultaneously targeting BCMA and GPRC5D prevents BCMA-escape driven relapse in multiple myeloma

Meeting Abstract

Fernandez de Larrea, C.; Staehr, M.; Lopez, A.; Chen, Y.; Purdon, T. J.; Ng, K. Y.; Wendel, H.; Brentjens, R. J.; Smith, E. L.
Blood (2019)

Fulltext@MSK | Save

Tandem autologous-autologous vs. autologous-allogeneic transplantation for newly diagnosed multiple myeloma: Pooled analysis of 1,338 patients from four trials with long-term follow up

Meeting Abstract

Costa, L. J.; Iacobelli, S.; Pasquini, M. C.; Modi, R.; Giaccone, L.; Bladé, J.; Schonland, S.; Evangelista, A.; Perez-Simon, J. A.; Hari, P.; more...
Blood (2019)

Fulltext@MSK | Save

Molecular mechanisms mediating relapse following ivosidenib monotherapy in patients with IDH1-mutant relapsed or refractory acute myeloid leukemia

Meeting Abstract

Choe, S.; Wang, H.; DiNardo, C. D.; Stein, E. M.; De Botton, S.; Fathi, A. T.; Tallman, M. S.; Kantarjian, H. M.; Stone, R. M.; Quek, L.; more...
Blood (2019)

Fulltext@MSK | Save